Central Trust Company’s Guardant Health GH Stock Holding History

Central Trust Company’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.05K	Buy	7 +2	+40%	+$218	﹤0.01%	1476
2026 Q1	$462	Hold	5	–	–	﹤0.01%	1500
2025 Q4	$511	Buy	+5	New	+$447	﹤0.01%	1444
2025 Q3	–	Sell	-9	Closed	-$469	–	1455
2025 Q2	$469	Hold	9	–	–	﹤0.01%	1404
2025 Q1	$384	Hold	9	–	–	﹤0.01%	1416
2024 Q4	$275	Hold	9	–	–	﹤0.01%	1415
2024 Q3	$207	Hold	9	–	–	﹤0.01%	1400
2024 Q2	$260	Hold	9	–	–	﹤0.01%	1389
2024 Q1	$186	Hold	9	–	–	﹤0.01%	1362
2023 Q4	$244	Hold	9	–	–	﹤0.01%	1367
2023 Q3	$267	Buy	+9	New	+$316	﹤0.01%	1346
2022 Q3	–	Sell	-20	Closed	-$1K	–	1346
2022 Q2	$1K	Hold	20	–	–	﹤0.01%	1293
2022 Q1	$1K	Sell	20 -280	-93%	-$19.2K	﹤0.01%	1302
2021 Q4	$30K	Hold	300	–	–	﹤0.01%	879
2021 Q3	$38K	Hold	300	–	–	﹤0.01%	806
2021 Q2	$37K	Sell	300 -505	-63%	-$67.9K	﹤0.01%	778
2021 Q1	$123K	Sell	805 -238	-23%	-$36K	﹤0.01%	571
2020 Q4	$134K	Sell	1,043 -15	-1%	-$1.73K	0.01%	539
2020 Q3	$118K	Sell	1,058 -389	-27%	-$35.6K	0.01%	527
2020 Q2	$117K	Buy	1,447 +1,303	+905%	+$105K	0.01%	506
2020 Q1	$10K	Hold	144	–	–	﹤0.01%	865
2019 Q4	$11K	Hold	144	–	–	﹤0.01%	927
2019 Q3	$9K	Hold	144	–	–	﹤0.01%	920
2019 Q2	$13K	Buy	+144	New	+$11K	﹤0.01%	873

Other funds holding GH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Central Trust Company's GH Position: Q2 2026 in Review

Central Trust Company increased its Guardant Health (GH) stake by 40% in Q2 2026, buying an estimated $218 and bringing the position to 7 shares worth $1.05K. The position accounts for ﹤0.01% of the portfolio, ranked #1476.

Central Trust Company first reported a position in GH in Q2 2019 and has held it in 24 quarters since. The position peaked at $134K in Q4 2020. 597 funds tracked by Wall St. Rank hold GH as of Q2 2026.

Central Trust Company held 7 shares of Guardant Health worth $1.05K as of Q2 2026.
Central Trust Company bought 2 Guardant Health shares in Q2 2026, an estimated $218.
Guardant Health made up ﹤0.01% of Central Trust Company's portfolio in Q2 2026, its #1476 holding.
Central Trust Company first reported a position in Guardant Health in Q2 2019 and has held it in 24 quarters since.
Central Trust Company's Guardant Health position peaked at $134K in Q4 2020.
597 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on Central Trust Company's 13F filing for Q2 2026, filed 31 Jul 2026.